metoclopramide has been researched along with Lupus Erythematosus, Systemic in 2 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two different types of drug eruptions were observed: five patients had development of a macular and partly papular or urticarial rash and angioedema and two patients had a generalized fixed drug eruption, primarily and predominantly at the sites of previous skin lesions of their underlying condition." | 5.28 | Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis. ( Aberer, W; Tappeiner, G; Zonzits, E, 1992) |
| "Hyperprolactinemia has been found in patients with systemic lupus erythematosus (SLE) and seems to be associated with clinical activity." | 1.32 | Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. ( Alarcón-Segovia, D; Alcocer-Varela, J; de la Cruz, DA; Larrea, F; Lava-Zavala, A; Méndez, I; Parra, A, 2004) |
| "Two different types of drug eruptions were observed: five patients had development of a macular and partly papular or urticarial rash and angioedema and two patients had a generalized fixed drug eruption, primarily and predominantly at the sites of previous skin lesions of their underlying condition." | 1.28 | Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis. ( Aberer, W; Tappeiner, G; Zonzits, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Méndez, I | 1 |
| Alcocer-Varela, J | 1 |
| Parra, A | 1 |
| Lava-Zavala, A | 1 |
| de la Cruz, DA | 1 |
| Alarcón-Segovia, D | 1 |
| Larrea, F | 1 |
| Zonzits, E | 1 |
| Aberer, W | 1 |
| Tappeiner, G | 1 |
2 other studies available for metoclopramide and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin.
Topics: Adult; Blotting, Western; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Hypothalamo-Hypo | 2004 |
Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis.
Topics: Adult; Biopsy; Cyclophosphamide; Dermatomyositis; Drug Eruptions; Drug Therapy, Combination; Female; | 1992 |